Neuropediatrics 2010; 41(3): 113-120
DOI: 10.1055/s-0030-1262839
Original Article

© Georg Thieme Verlag KG Stuttgart · New York

Seizure and Cognitive Outcomes in Children and Adolescents with Epilepsy Treated with Topiramate

U. Brandl1 , G. Kurlemann2 , B. Neubauer3 , K. Rettig4 , B. Schäuble6 , A. Schreiner5
  • 1Department of Neuropediatrics, University Hospital, Jena, Germany
  • 2Department of Neuropediatrics, University Hospital, Münster, Germany
  • 3Department of Neuropediatrics, University Hospital, Giessen, Germany
  • 4Bureau for Evaluation and Quality Assurance in Medicine (G.E.M.), Meerbusch, Germany
  • 5Department of Medical Affairs, Janssen-Cilag Europe Middle-East and Africa, Neuss, Germany
  • 6Medical and Scientific Affairs, Janssen Cilag GmbH, Neuss, Germany
Weitere Informationen

Publikationsverlauf

received 03.03.2010

accepted 08.07.2010

Publikationsdatum:
21. September 2010 (online)

Preview

Abstract

This 12-week open label study explored cognitive and seizure outcomes of 53 children treated with topiramate (TPM). The digit symbol test and verbal learning memory test were administered at baseline and study endpoint. Topiramate was started either in monotherapy or add-on therapy. Overall, 57% of children experienced a ≥50% seizure reduction, 36% became seizure free and cognitive testing revealed no significant changes during TPM therapy. Due to the heterogeneity of the study population, post hoc analyses were added to compare patients in initial or conversion to TPM monotherapy as well as patients who continued add-on therapy. Verbal learning memory test parameters showed neither significant differences within any subgroup comparing baseline with endpoint nor significant differences between described subgroups except for one finding. The digit symbol test revealed no differences between each subgroup between baseline and endpoint. Comparing pre-post differences, TPM monotherapy was associated with better cognitive outcomes than treatment in add-on therapy. These results have to be interpreted with caution given the short study duration and the heterogeneity of the study population. Despite these limitations, our overall results suggest that treatment with topiramate is associated with improved seizure control without significant changes in cognitive functions at the low doses tested.

References

Correspondence

Barbara SchäubleMD, PhD 

Medical and Scientific Affairs

Janssen Cilag GmbH

Johnson & Johnson Platz 1

41470 Neuss

Germany

Telefon: +49/2137/955 398

Fax: +49/2137/955 486

eMail: BSchaeu2@its.jnj.com